<p><img src="https://imageproxy.pbkrs.com/https://invezz.com/wp-content/uploads/2021/11/cassava-sciences.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://invezz.com/wp-content/uploads/2021/11/cassava-sciences.jpg"/></p>
<p>Cassava Sciences（納斯達克：SAVA）股價已經跌至谷底。曾經是一隻備受追捧的股票，今年已經下跌超過 45%，從歷史最高點下跌超過 90%，市值超過 5.3 億美元。在股價飆升時，該公司估值曾超過 74 億美元。</p>
<h2>跌入谷底的繼續</h2>
<p>Cassava Sciences 是阿爾茨海默病研究領域的領先公司之一，在交易員中備受矚目。隨着 FDA 批准白光公司的 aducanumab 並開始以每年 26500 美元的價格銷售，該公司在 2021 年人氣飆升。</p>
<p>然而，最近，儘管阿爾茨海默病行業仍然強勁，但有跡象表明其複雜性使許多投資者退縮。今年早些時候，白光公司宣佈將重新調整在該行業的資源，停止開發和商業化 ADUHELM。</p>
<p>Cassava Sciences 希望憑藉其名為 Simufilam 的藥物成為該行業的主要參與者。該公司希望該藥物最終能夠獲得 FDA 的授權。</p>
<p>考慮到阿爾茨海默病影響美國和全球超過 500 萬人，這是一個龐大的行業。</p>
<p>然而，該公司在過去幾年中承受了巨大壓力，這導致股價暴跌。儘管 Simufilam 處於第三階段試驗中，但人們對其數據完整性表示擔憂。</p>
<h2>王浩巖問題持續</h2>
<p>這些擔憂在上週加劇，當時前科學顧問王浩巖被指控欺詐美國國立衞生研究院（NIH）。當局稱他在 2017 年至 2018 年之間發送了撥款申請並獲得了 1600 萬美元的撥款。他將這些撥款歸為自己和 Cassava Sciences。</p>
<p>王浩巖長期以來一直備受關注。在《紐約時報》的一篇報道中，對他的工作進行的調查顯示，他因未能保留或提供原始數據而被指責魯莽。</p>
<p>新的訴訟意味着該公司及其試驗可能在未來幾個月內接受更多審查。此外，阿爾茨海默病是一種治療難度極大的疾病，這一點由許多失敗的測試所證明。</p>
<p>此外，有關數據管理不當和公司缺乏原始數據的指控。一些分析師也質疑該公司的藥物是否有效，一些人指出王浩巖曾篡改結果。</p>
<p>最近的財務結果顯示，Cassava Sciences 的業務出現了 1990 萬美元的營業虧損。其中大部分資金用於研發。其淨利潤超過 2500 萬美元，得益於權證負債公允價值的增值。</p>
<p>該公司還擁有強勁的資產負債表，使其無需籌集資金即可運營。其現金及等價物超過 1200 萬美元。這意味着該公司可能需要在 2025 年或 2026 年籌集資金。</p>
<p>儘管如此，我認為 Cassava Sciences 是一家高風險公司，其 Simufilam 藥物面臨着重大風險。</p>
<h2>Cassava Sciences 股價分析</h2>
<p><img src="https://imageproxy.pbkrs.com/https://invezz.com/wp-content/uploads/2024/07/Cassava-Sciences-stock-1024x570.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://invezz.com/wp-content/uploads/2024/07/Cassava-Sciences-stock-1024x570.png"/></p>
<p>TradingView 提供的 SAVA 圖表</p>
<p>周線圖顯示，SAVA 股價在過去幾年中一路下跌。上週五，股價跌破了 12.33 美元的關鍵支撐位，創下 2023 年 10 月和 2022 年 7 月的最低點。</p>
<p>Cassava Sciences 的股價一直低於 50 周和 100 周指數移動平均線（EMA）。因此，股價可能會繼續下跌，賣方將瞄準 10 美元的關鍵支撐位。這意味着它可能會從當前水平下跌約 20%。跌破該點可能會下跌至 6.40 美元的關鍵點。</p>
<p>本文最初發表於 Invezz，轉載請註明出處。</p>

SAVA

<p>今年以來，Cassava Sciences（納斯達克股票代碼：SAVA）股價已下跌超過 45%，距離歷史最高點已下跌超過 90%。該公司的藥物 Simufilam 正在進行第三階段臨牀試驗，但面臨數據完整性問題和操縱指控的擔憂。最近針對一位前科學顧問的欺詐指控進一步引起了審查。儘管財務狀況強勁且未來可能需要籌集資金，但 Cassava Sciences 仍然是一項高風險投資</p>

<p><img src="https://imageproxy.pbkrs.com/https://invezz.com/wp-content/uploads/2021/11/cassava-sciences.jpg" alt="" original-src="https://invezz.com/wp-content/uploads/2021/11/cassava-sciences.jpg"/></p>
<p>Cassava Sciences (NASDAQ: SAVA) stock price has become a fallen angel. Once a high popular stock, it has crashed by over 45% this year and by more than 90% from its all-time high, giving it a market cap of over $530 million. At its peak, the company had a valuation of over $7.4 billion.</p>
<div class="lb-trans"><p>Cassava Sciences（納斯達克：SAVA）股價已經跌至谷底。曾經是一隻備受追捧的股票，今年已經下跌超過 45%，從歷史最高點下跌超過 90%，市值超過 5.3 億美元。在股價飆升時，該公司估值曾超過 74 億美元。</p>
</div><h2>Fall from grace continues</h2>
<div class="lb-trans"><h2>跌入谷底的繼續</h2>
</div><p>Cassava Sciences, a leading company in Alzheimer’s research, was one of the hottest companies among traders. Its popularity soared in 2021 as most investors focused on Alzheimer after the FDA approved Biogen’s aducanumab, which it started selling at $26,500 per year.</p>
<div class="lb-trans"><p>Cassava Sciences 是阿爾茨海默病研究領域的領先公司之一，在交易員中備受矚目。隨着 FDA 批准白光公司的 aducanumab 並開始以每年 26500 美元的價格銷售，該公司在 2021 年人氣飆升。</p>
</div><p>Recently, however, while the Alzheimer’s industry is still robust, there are signs that its complexity has made many investors to pull back. Earlier this year, Biogen announced that it would reprioritise its resources in the industry by discontinuing the development and commercialisation of ADUHELM.</p>
<div class="lb-trans"><p>然而，最近，儘管阿爾茨海默病行業仍然強勁，但有跡象表明其複雜性使許多投資者退縮。今年早些時候，白光公司宣佈將重新調整在該行業的資源，停止開發和商業化 ADUHELM。</p>
</div><p>Cassava Sciences is hoping to become a major player in the industry, thanks to its drug, which is known as Simufilam. The company hopes that the drug will ultimately receive authorisation by the FDA.</p>
<div class="lb-trans"><p>Cassava Sciences 希望憑藉其名為 Simufilam 的藥物成為該行業的主要參與者。該公司希望該藥物最終能夠獲得 FDA 的授權。</p>
</div><p>Alzheimer’s is a big industry considering that it affects over 5 million people in the United States and around the world.</p>
<div class="lb-trans"><p>考慮到阿爾茨海默病影響美國和全球超過 500 萬人，這是一個龐大的行業。</p>
</div><p>However, the company has come under intense pressure in the past few years, which has contributed to the stock’s collapse. While simufilam is in the third phase of trial, there have been concerns about its data integrity.</p>
<div class="lb-trans"><p>然而，該公司在過去幾年中承受了巨大壓力，這導致股價暴跌。儘管 Simufilam 處於第三階段試驗中，但人們對其數據完整性表示擔憂。</p>
</div><h2>Hoau-Yan Wang problems continue</h2>
<div class="lb-trans"><h2>王浩巖問題持續</h2>
</div><p>These concerns accelerated on Friday when Hoau-Yan Wang, a former scientific advisor was accused of defauding the National Institutes of Health (NIH). Authorities alleged that he defrauded the government by sending grant applications and receiving $16 million in grants between 2017 and 2018. He took these grants on his behalf and that of Cassava Sciences.</p>
<div class="lb-trans"><p>這些擔憂在上週加劇，當時前科學顧問王浩巖被指控欺詐美國國立衞生研究院（NIH）。當局稱他在 2017 年至 2018 年之間發送了撥款申請並獲得了 1600 萬美元的撥款。他將這些撥款歸為自己和 Cassava Sciences。</p>
</div><p>Wang has been in the spotlight for a long time. In this New York Times report, an investigation into his work showed that he was reckless for failing to keep or provide original data.</p>
<div class="lb-trans"><p>王浩巖長期以來一直備受關注。在《紐約時報》的一篇報道中，對他的工作進行的調查顯示，他因未能保留或提供原始數據而被指責魯莽。</p>
</div><p>The new filing means that the company and its trial will likely get into more scrutiny in the coming months. Besides, Alzheimer’s is one of the toughest diseases to treat, as evidenced by the many failed tests.</p>
<div class="lb-trans"><p>新的訴訟意味着該公司及其試驗可能在未來幾個月內接受更多審查。此外，阿爾茨海默病是一種治療難度極大的疾病，這一點由許多失敗的測試所證明。</p>
</div><p>Also, there have been allegations of data mismanagement and the lack of raw data in the company. Some analysts also question whether the company’s drug is effective after all, with some noting that Wang had manipulated the results.</p>
<div class="lb-trans"><p>此外，有關數據管理不當和公司缺乏原始數據的指控。一些分析師也質疑該公司的藥物是否有效，一些人指出王浩巖曾篡改結果。</p>
</div><p>The most recent financial results showed that Cassava Sciences’ business had an operating loss of $19.9 million. Most of these funds went to researcg and development. Its net profit came in at over $25 million, thanks to the gain in fair value of warrant liabilities.</p>
<div class="lb-trans"><p>最近的財務結果顯示，Cassava Sciences 的業務出現了 1990 萬美元的營業虧損。其中大部分資金用於研發。其淨利潤超過 2500 萬美元，得益於權證負債公允價值的增值。</p>
</div><p>The company also has a strong balance sheet that gives it room to operate without the need to raise cash. It had over $12 million in cash and equivalents. This means that the company will likely need to raise cash in 2025 or 2026.</p>
<div class="lb-trans"><p>該公司還擁有強勁的資產負債表，使其無需籌集資金即可運營。其現金及等價物超過 1200 萬美元。這意味着該公司可能需要在 2025 年或 2026 年籌集資金。</p>
</div><p>Still, I believe that Cassava Sciences is a high-risk company whose simufilam drug faces substantial risks ahead.</p>
<div class="lb-trans"><p>儘管如此，我認為 Cassava Sciences 是一家高風險公司，其 Simufilam 藥物面臨着重大風險。</p>
</div><h2>Cassava Sciences stock price analysis</h2>
<div class="lb-trans"><h2>Cassava Sciences 股價分析</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://invezz.com/wp-content/uploads/2024/07/Cassava-Sciences-stock-1024x570.png" alt="" original-src="https://invezz.com/wp-content/uploads/2024/07/Cassava-Sciences-stock-1024x570.png"/></p>
<p>SAVA chart by TradingView</p>
<div class="lb-trans"><p>TradingView 提供的 SAVA 圖表</p>
</div><p>The weekly chart shows that the SAVA share price has been in a freefall in the past few years. On Friday, the stock moved below the key support at $12.33, its lowest swing in October 2023 and July 2022.</p>
<div class="lb-trans"><p>周線圖顯示，SAVA 股價在過去幾年中一路下跌。上週五，股價跌破了 12.33 美元的關鍵支撐位，創下 2023 年 10 月和 2022 年 7 月的最低點。</p>
</div><p>Cassava Sciences’ share price has remained below the 50-week and 100-week Exponential Moving Averages (EMA). Therefore, the stock will likely continue falling as sellers target the key support at $10. This means that it could crash by about 20% from the current level. A drop below that point could drop to the key point at $6.40.</p>
<div class="lb-trans"><p>Cassava Sciences 的股價一直低於 50 周和 100 周指數移動平均線（EMA）。因此，股價可能會繼續下跌，賣方將瞄準 10 美元的關鍵支撐位。這意味着它可能會從當前水平下跌約 20%。跌破該點可能會下跌至 6.40 美元的關鍵點。</p>
</div><p>The post Cassava Sciences stock forecast: is it safe to buy the SAVA dip? appeared first on Invezz</p>
<div class="lb-trans"><p>本文最初發表於 Invezz，轉載請註明出處。</p>
</div>

Cassava Sciences 股票預測：現在買入 SAVA 的低點是否安全？